EOLS
Drug Manufacturers - Specialty & Generic · Healthcare
CFO
2022-09-05–2025-06-13
Equibles does not estimate personal net worth.
Earlier roles on record: CFO at Evolus, Inc. (EOLS) until June 13, 2025. Evolus, Inc. reported in an 8-K filed May 27, 2025 that Sandra Beaver resigned as Chief Financial Officer, effective June 13, 2025. The proxy statement of Evolus, Inc. reports total compensation of $1,699,898 for Sandra Beaver in fiscal 2025, including a base salary of $231,904. Disclosed compensation is on record for 5 fiscal years. Sandra Beaver has spoken on 10 earnings calls across 1 company, most recently for Evolus, Inc. on May 7, 2025. The companies whose calls Sandra Beaver spoke on are classified in the Healthcare sector.
“Sandra Beaver had informed the Company of her decision to voluntarily resign from her position as the Chief Financial Officer, effective as of June 13, 2025, to pursue another opportunity.”
“As we enter the second quarter, Evolysse is well-positioned to deliver on our full year guidance.”
“I would like to begin by congratulating the Evolus team for delivering an outstanding fourth quarter and close to 2024.”
“Our financial results this quarter are a testament to the underlying operating strength of our business. I would like to congratulate the Evolus team for delivering another quarter of above-market sales growth and efficient operating expense management.”
“I would like to congratulate the Evolus team on another quarter of above-market sales growth and prudent management of our operating expenses that enabled us to achieve profitability two quarters earlier than anticipated.”
“I would like to congratulate the Evolus team for another quarter of above-market sales growth and operating expense discipline. These above-market Q1 results represent a meaningful step towards achieving our top-line guidance and delivering profitability for Q4 2024.”
2022-09-05–2025-06-13
Start not stated–2025-06-13
EOLS
Drug Manufacturers - Specialty & Generic · Healthcare
CFO
2022-09-05–2025-06-13
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Evolus, Inc. (EOLS) | Former Chief Financial Officer | $231,904 | $1,699,898 |
| 2024 | Evolus, Inc. (EOLS) | Chief Financial Officer | $477,625 | $1,911,323 |
| 2023 | Evolus, Inc. (EOLS) | Chief Financial Officer | $437,500 | $2,459,737 |
| 2022 | Evolus, Inc. (EOLS) | Chief Financial Officer | $136,818 | $1,827,407 |
| 2021 | Evolus, Inc. (EOLS) | Chief Financial Officer | — | — |